Search

Reading Time: < 1 minutes “With the new day comes new strength and new thoughts.” — Eleanor Roosevelt

Article

Reading Time: 2 minutes The stakes for delays in clinical research are high.

Article

Reading Time: 2 minutes “How many of your colleagues can describe and visualize the actual patient experience?”

Article

Reading Time: 2 minutes PhaseBio—a clinical-stage biopharma company developing improved biotherapeutics for orphan diseases, with an initial focus on cardiopulmonary disorders—has the distinction of being Medidata’s 1,000th customer.

Article

Reading Time: < 1 minutes Digital transformation: this is one of the hottest topics in our industry today, creating both opportunities and challenges for our customers. For pharmaceutical, biotech, and medical device companies, the promise of making data-driven, insights-led decisions in real-time means getting the right treatments to the right patients at the right time. To truly realize this potential, they need to rely on combined insights from both clinical and commercial data.

Article

Reading Time: < 1 minutes So far Edge Trial Assurance has been used in 30 trials. It has detected 50-75 data anomalies in every single trial.

Article

Reading Time: 3 minutes This blog was authored by Phyllisa Deroze. Phyllisa is a global diabetes patient advocate, the Director of Content Strategy at dQ&A, and a member of Medidata’s Patient Insights Board. It wasn’t the diagnosis of diabetes that led me to become a diabetes advocate; it was the various experiences of being mistreated and misdiagnosed while searching […]

Article

Reading Time: 2 minutes When it comes to submitting new drug applications to FDA, it’s safe to assume that the prospect of receiving a complete response letter keeps pharma executives up at night. The risks associated with regulatory submission can have a substantial impact on a business, and approval delays due to data issues can cost a company millions. As a former FDA reviewer, I’ve seen just about everything when it comes to data quality issues that can derail drug approvals. Luckily, today these kinds of risks can be mitigated using sophisticated data analytics.

Article

Reading Time: < 1 minutes Nearly 20 years ago Medidata was built around modernizing data capture and management, which ultimately became Rave. Today, we can confidently say we’re so much more than that.

Article

Reading Time: 2 minutes Last month Medidata celebrated Black History Month, and we took time to come together for our speaker series MediTalk to discuss how our industry can close the diversity gap in clinical trials.

Article

Reading Time: 2 minutes Join us next week in Frankfurt to hear from Bayer Head of Data Sciences & Analytics Benedikt Egersdoerfer and others to exchange best practices in transforming clinical development.

Article

Reading Time: 3 minutes Once a problem is detected, we must ensure that it is documented, along with its associated actions and resolutions.

Article